12/4
09:43 am
fbrx
Forte Biosciences, Inc. (NASDAQ: FBRX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $64.00 price target on the stock.
Medium
Report
Forte Biosciences, Inc. (NASDAQ: FBRX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $64.00 price target on the stock.
11/25
09:00 am
fbrx
Forte Biosciences to Host R&D Day December 3, 2024
Medium
Report
Forte Biosciences to Host R&D Day December 3, 2024
11/20
09:00 am
fbrx
Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications
High
Report
Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications
11/15
06:04 pm
fbrx
Forte Biosciences, Inc. (NASDAQ: FBRX) had its price target raised by analysts at Chardan Capital from $3.00 to $64.00. They now have a "buy" rating on the stock.
Medium
Report
Forte Biosciences, Inc. (NASDAQ: FBRX) had its price target raised by analysts at Chardan Capital from $3.00 to $64.00. They now have a "buy" rating on the stock.
11/14
04:01 pm
fbrx
Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business Update
Medium
Report
Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business Update